Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-α and melphalan

Annals of Surgical Oncology

Volumn 10, Issue 5, 2003, Pages 562-568

  Hohenberger, Peter ^a,b   Latz, Eicke ^a   Kettelhack, Christoph ^a   Rezaei, Amir Hossein ^a   Schumann, Ralf ^a   Schlag, Peter M ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Section of Pathology   (Germany)

Author keywords

Cytokine; Isolated limb perfusion; Pentoxifyllin; Septic shock; SIRS; TNF

Indexed keywords

DOBUTAMINE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE BINDING PROTEIN; MELPHALAN; NORADRENALIN; PENTOXIFYLLINE; PROCALCITONIN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXTRACORPOREAL CIRCULATION; FEMALE; HEART INDEX; HUMAN; LIMB PERFUSION; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; MELANOMA; PROTEIN BLOOD LEVEL; REPERFUSION; SEPTIC SHOCK; SOFT TISSUE SARCOMA; SWAN GANZ CATHETER; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC VASCULAR RESISTANCE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; INFLAMMATION; LIMB; MIDDLE AGED; REGIONAL PERFUSION; SARCOMA; SKIN TUMOR; SOFT TISSUE TUMOR; SYNDROME; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; ENZYME INHIBITORS; EXTREMITIES; FEMALE; HUMANS; INFLAMMATION; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; PENTOXIFYLLINE; SARCOMA; SHOCK, SEPTIC; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS; SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0042285874     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2003.10.005     Document Type: Article

References (40)

1. Eggermont AM, Schraffordt KH, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. Cumulative multicenter European experience. Ann Surg 1996;224:756-64.
2. Eggermont AM, Schraffordt KH, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996;14:2653-65.
3. Fraker DL, Alexander HR, Ross M, et al. A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon-gamma (IFN). Ann Surg Oncol 2002;9(Suppl):S8.
4. Bartlett DL, Ma G, Alexander HR, Libutti SK, Fraker DL. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 1997;80:2084-90.
5. Thom AK, Alexander HR, Andrich MP, Barker WC, Rosenberg SA, Fraker DL. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon-gamma, and melphalan. J Clin Oncol 1995;13: 264-73.
6. Zwaveling JH, Maring JK, Moshage H, et al. Role of nitric oxide in recombinant tumor necrosis factor-α-induced circulatory shock: a study in patients treated for cancer with isolated limb perfusion. Crit Care Med 1996;24:1806-10.
7. Eggimann P, Chiolèro R, Chassot P-G, Lienard D, Gerain J, Lejeune F. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest 1995;107:1074-82.
8. Kettelhack C, Hohenberger P, Schulze G, Kilpert B, Schlag PM. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan. Crit Care Med 2000; 28:1040-6.
9. Vrouenraets BC, Kroon BB, Ogilvie AC, et al. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 1999;6:405-12.
10. Deleted in proofs.
11. Schandene L, Vandenbussche P, Crusiaux A, et al. Differential effects of pentoxifylline on the production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) by monocytes and T cells. Immunology 1992;76:30-4.
12. Schade UF. Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ Shock 1990;31:171-81.
13. Schumann RR, Kirschning CJ, Unbehaun A, et al. The lipopolysaccharide- binding protein is a secretory class 1 acute-phase protein whose gene is transcriptionally activated by APRF/STAT/3 and other cytokine-inducible nuclear proteins. Mol Cell Biol 1996; 16:3490-503.
14. Wieberdink J, Benckhuysen C, Braat RP, Van Slooten EA, Olthuis GAA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-10.
15. Sprenger HJ, Markwardt J, Schlag PM. Quantitative Leckkontrolle mit Radionuckliden bei der isolierten Extremitatenperfusion. Nuklearmedivn 1994;33:248-53.
16. Eggermont AMM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. Ann Surg 1996;224:756-65.
17. Zweigner J, Gramm HJ, Singer OC, Wegscheider K, Schumann RR. High concentrations of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. Blood 2001;98: 3800-8.
18. Hohenberger P, Haier J, Schlag PM. Rhabdomyolysis and renal function impairment after isolated limb perfusion - comparison between the effects of perfusion with rhTNF-alpha and a "triple-drug" regimen. Eur J Cancer 1997;33:596-601.
19. Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 1991;110:192-8.
20. Zheng H, Crowley JJ, Chan JC, et al. Attenuation of tumor necrosis factor-induced endothelial cell cytotoxicity and neutrophil chemiluminescence. Am Rev Respir Dis 1990;142:1073-8.
21. Currie MS, Rao KM, Padmanabhan J, Jones A, Crawford J, Cohen HJ. Stimulus-specific effects of pentoxifylline on neutrophil CR3 expression, degranulation, and superoxide production. J Leukoc Biol 1990;47:244-50.
22. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990; 172:391-4.
23. Crouch SP, Fletcher J. Effect of ingested pentoxifylline on neutrophil superoxide anion production. Infect Immun 1992;60:4504-9.
24. Thiel M, Bardenheuer H, Poch G, Madel C, Peter K. Pentoxifylline does not act via adenosine receptors in the inhibition of the superoxide anion production of human polymorphonuclear leukocytes. Biochem Biophys Res Commun 1991;180:53-8.
25. Reynolds H. Pentoxifylline - more evidence that it improves host defenses during sepsis. Crit Care Med 1999;27:681-3.
26. Dolan S, Lewis H, Campbell G, McCluggage G, Halliday MI, Rowlands BJ. Pentoxyphyllin improves survival and reduces the concentration of tumor necrosis factor in acute pancreatitis. Br J Surg 1995;82:1568.
27. Heller S, Weber K, Heller A, Urbaschek R, Koch T. Pentoxifylline improves bacterial clearance during hemorrhage and endotoxemia. Crit Care Med 1999;27:756-63.
28. Staudinger T, Presterl E, Graninger W, et al. Influence of pentoxifylline on cytokine levels and inflammatory parameters in septic shock. Intensive Care Med 1996;22:888-93.
29. Bacher A, Mayer N, Klimscha W, Oismuller C, Steltzer H, Hammerle A. Effects of pentoxifylline on hemodynamics and oxygenation in septic and nonseptic patients. Crit Care Med 1997;25:795-800.
30. Zeni F, Pain P, Vindimian M, et al. Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study. Crit Care Med 1996;24:207-14.
31. Staubach KH, Schroder J, Stuber F, Gehrke K, Traumann E, Zabel P. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study. Arch Surg 1998;133:94-100.
32. De Werra I, Jaccard C, Corradin SB, et al. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 1997;25: 607-13.
33. Myc A, Buck J, Gonin J, Reynolds B, Hammerling U, Emanuel D. The level of lipopolysaccharide-binding protein is significantly increased in plasma in patients with the systemic inflammatory response syndrome. Clin Diagn Lab Immunol 1997;4:113-6.
34. Kettelhack C, Hohenberger P, Furchtbar S, Schulze G, Schlag PM. Procalcitonin als Marker der systemischen inflammatorischen Reaktion nach isolierter Extremitätenperfusion. Langenbecks Arch Chir 1998;115(Suppl 1):397-8.
35. Montravers P, Fagon JY, Gilbert C, Blanchet F, Novara A, Chastre J. Pilot study of cardiopulmonary risk from pentoxifylline in adult respiratory distress syndrome. Chest 1993;103:1017-22.
36. Lienard D, Ewalenko P, Delmotte JJ, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60.
37. Lienard D, Eggermont AMM, Schraffordt Koops H, et al. Isolated perfusion of the limb with high-dose tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res 1994;4(Suppl 1):21-6.
38. Lans TE, Bartlett DL, Libutti SK, et al. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion. Clin Cancer Res 2001;7:784-90.
39. Gnant MF, Turner EM, Alexander H-RJ. Effects of hyperthermia and tumour necrosis factor on inflammatory cytokine secretion and procoagulant activity in endothelial cells. Cytokine 2000;12:339-47.
40. Ducloux D, Bresson-Vautrin C, Chalopin J. Use of pentoxifylline in membranous nephropathy. Lancet 2001;357:1672-3.